Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC

Caulier, A.; Drumez, E.; Gauthier, J.; Robin, M.; Blaise, D.; Beguin, Yves; Michallet, M.; Chevallier, P.; Bay, J.-O.; Vigouroux, S.; Desbrosses, Y.; Cornillon, J.; Nguyen, S.; Dauriac, C.; de Latour, R. P.; Lioure, B.; Rohrlich, P.-S.; Carré, M.; Bourhis, J.-H.; Huynh, A.; Suarez, F.; Garnier, F.; Duhamel, A.; Yakoub-Agha, I.

doi:10.1016/j.retram.2018.08.003

Article (Scientific journals)

Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC

Caulier, A.; Drumez, E.; Gauthier, J. et al.

2019 • In Current Research in Translational Medicine, 67, p. 8-15

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/232598

DOI
10.1016/j.retram.2018.08.003

PubMed
30206045

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

423.pdf

Publisher postprint (654.98 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

myelodysplastic syndrome; prognostic scoring system; early post-transplant complications; allogeneic hematopoietic cell; transplantation

Abstract :

[en] Purpose: We developed a prognostic scoring system to evaluate the prognosis of myelodysplastic syndrome (MDS) patients surviving more than 100 days allogeneic hematopoietic cell transplantation after (allo-HCT). Patients and methods: We performed a landmark analysis on a derivation cohort of 393 cases to identify prognostic factors for 3-year overall survival. Potential predictor variables included demographic and clinical data, transplantation modalities and early post-transplant complications. The scoring system was tested against a validation cohort which included 391 patients. Results: Complications occurring before day 100 such as relapse [HR = 6.7; 95%CI, 4.5-10.0] (4 points), lack of platelet recovery [HR, 3.6; 95%CI, 2.2-5.8] (2 points), grade-II acute GVHD [HR = 1.7; 95%CI, 1.2-2.5] (1 point) and grade-III/IV [HR = 2.6; 95%CI, 1.8 -3.8] (2 points) were the only independent predictors of 3-year OS. The 3-year OS associated with low (0), intermediate (1-3) and high (≥4) risk scores was respectively 70%, 46% and 6%. The model performed consistently in both cohorts, with good calibration. Conclusion: This post-transplant scoring system is a powerful predictor of outcome after allo-HCT for MDS, and can provide useful guidance for clinicians. Additional studies are required to evaluate this scoring system for other hematologic malignancies. © 2018

Disciplines :

Hematology

Author, co-author :

Caulier, A.; Hématologie, Centre Hospitalier Universitaire (CHU) Sud, Amiens, France

Drumez, E.; Univ. Lille, CHU Lille, EA 2694 – Santé publique: épidémiologie et qualité des soins, Unité de biostatistique, Lille, F-59000, France

Gauthier, J.

Robin, M.; Hématologie-Transplantation, AP-HP, Hôpital Saint Louis, Université Paris 7, Paris, France

Blaise, D.; Hématologie, Institut Paoli-Calmettes, Marseille, France

Beguin, Yves ; Université de Liège - ULiège > GIGA-R : Hématologie

Michallet, M.; Hématologie, CHU Lyon Sud, Lyon, France

Chevallier, P.; Hématologie, CHU, Nantes, France

Bay, J.-O.; Hématologie, CHU, Clermont Ferrand, France

Vigouroux, S.; Hématologie, CHU, Bordeaux, France

More authors (14 more)

Language :

English

Title :

Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC

Publication date :

2019

Journal title :

Current Research in Translational Medicine

ISSN :

2452-3186

Publisher :

Elsevier Masson SAS

Volume :

Pages :

8-15

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 05 February 2019

Statistics

Number of views

119 (7 by ULiège)

Number of downloads

255 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Garcia-Manero, G., Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am J Hematol. 90:September (9) (2015), 831–841.
Yakoub-Agha, I., de La Salmonière, P., Ribaud, P., Sutton, L., Wattel, E., Kuentz, M., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol Off J Am Soc Clin Oncol. 18:March (5) (2000), 963–971.
Gooley, T.A., Chien, J.W., Pergam, S.A., Hingorani, S., Sorror, M.L., Boeckh, M., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 363:November (22) (2010), 2091–2101.
Horan, J.T., Logan, B.R., Agovi-Johnson, M.-A., Lazarus, H.M., Bacigalupo, A.A., Ballen, K.K., et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?. J Clin Oncol Off J Am Soc Clin Oncol. 29:March (7) (2011), 805–813.
Della Porta, M.G., Alessandrino, E.P., Bacigalupo, A., van Lint, M.T., Malcovati, L., Pascutto, C., et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 123:April (15) (2014), 2333–2342.
Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:September (12) (2012), 2454–2465.
Shaffer, B.C., Ahn, K.W., Hu, Z.-H., Nishihori, T., Malone, A.K., Valcarcel, D., et al. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol. 34:June (16) (2016), 1864–1871.
Damaj, G., Duhamel, A., Robin, M., Beguin, Y., Michallet, M., Mohty, M., et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol Off J Am Soc Clin Oncol. 30:December (36) (2012), 4533–4540.
Guièze, R., Damaj, G., Pereira, B., Robin, M., Chevallier, P., Michallet, M., et al. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 22:February (2) (2016), 240–247.
Gauthier, J., Damaj, G., Langlois, C., Robin, M., Michallet, M., Chevallier, P., et al. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy. Transplantation. 99:August (8) (2015), 1672–1680.
Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:March (6) (1997), 2079–2088.
Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:July (2) (2006), 419–425.
Bacigalupo, A., Ballen, K., Rizzo, D., Giralt, S., Lazarus, H., Ho, V., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 15:December (12) (2009), 1628–1633.
Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:June (6) (1995), 825–828.
Moreau, A.-S., Bourhis, J.-H., Contentin, N., Couturier, M.-A., Delage, J., Dumesnil, C., et al. Transfer of allogeneic stem cell transplant recipients to the intensive care unit: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC). Bull Cancer (Paris). 103:November (11S) (2016), S220–S228.
Harrell, F.E., Lee, K.L., Mark, D.B., Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 15:February (4) (1996), 361–387.
Schoenfeld, D., Partial Residuals for The Proportional Hazards Regression Model. Biometrika., 69(April (1)), 1982, 239.
van Buuren, S., Groothuis-Oudshoorn, K., mice : Multivariate Imputation by Chained Equations in R. J Stat Softw [Internet]. [cited 2016 Mar 9]; 45(3). Available from: 2011 http://www.jstatsoft.org/v45/i03/.
Royston, P., Moons, K.G.M., Altman, D.G., Vergouwe, Y., Prognosis and prognostic research: Developing a prognostic model. BMJ, 338, 2009, b604.
Neumann, F., Lobitz, O., Fenk, R., Bruns, I., Köstering, M., Steiner, S., et al. The sepsis-related Organ Failure Assessment (SOFA) score is predictive for survival of patients admitted to the intensive care unit following allogeneic blood stem cell transplantation. Ann Hematol. 87:April (4) (2008), 299–304.
Azoulay, E., Pène, F., Darmon, M., Lengliné E., Benoit, D., Soares, M., et al. Managing critically Ill hematology patients: Time to think differently. Blood Rev. 29:November (6) (2015), 359–367.
Bayraktar, U.D., Shpall, E.J., Liu, P., Ciurea, S.O., Rondon, G., de Lima, M., et al. Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. J Clin Oncol Off J Am Soc Clin Oncol 31:November (33) (2013), 4207–4214.
Townsend, W.M., Holroyd, A., Pearce, R., Mackinnon, S., Naik, P., Goldstone, A.H., et al. Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning. Br J Haematol 161:May (4) (2013), 578–586.
Azoulay, E., Mokart, D., Pène, F., Lambert, J., Kouatchet, A., Mayaux, J., et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium–a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol Off J Am Soc Clin Oncol. 31:August (22) (2013), 2810–2818.
Moreau, A.-S., Seguin, A., Lemiale, V., Yakoub-Agha, I., Girardie, P., Robriquet, L., et al. Survival and prognostic factors of allogeneic hematopoietic stem cell transplant recipients admitted to intensive care unit. Leuk Lymphoma 55:June (6) (2014), 1417–1420.
Pène, F., Aubron, C., Azoulay, E., Blot, F., Thiéry, G., Raynard, B., et al. Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol Off J Am Soc Clin Oncol. 24:February (4) (2006), 643–649.
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., Del Cañizo, C., et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:October (17) (2013), 2943–2964.
Alzahrani, M., Power, M., Abou Mourad, Y., Barnett, M., Broady, R., Forrest, D., et al. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 24:June (6) (2018), 1209–1215.
Kim, D.H., Sohn, S.K., Jeon, S.B., Baek, J.H., Kim, J.G., Lee, N.Y., et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant. 37:January (1) (2006), 101–108.
Ramírez, P., Brunstein, C.G., Miller, B., Defor, T., Weisdorf, D., Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival. Bone Marrow Transplant. 46:July (7) (2011), 981–986.
Dominietto, A., Raiola, A.M., van Lint, M.T., Lamparelli, T., Gualandi, F., Berisso, G., et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 112:January (1) (2001), 219–227.
Olsson, R.F., Logan, B.R., Chaudhury, S., Zhu, X., Akpek, G., Bolwell, B.J., et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 29:August (8) (2015), 1754–1762.
Matsumura-Kimoto, Y., Inamoto, Y., Tajima, K., Kawajiri, A., Tanaka, T., Hirakawa, T., et al. Association of cumulative steroid dose with risk of infection after treatment for severe acute graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant., 8(March), 2016.
Duléry, R., Mohty, M., Duhamel, A., Robin, M., Beguin, Y., Michallet, M., et al. Antithymocyte Globulin before Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Study from the French Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 20:May (5) (2014), 646–654.
Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:February (2) (2014), 241–247.